Search

Your search keyword '"Kastelein, John J.P."' showing total 1,080 results
Start Over Author "Kastelein, John J.P."
1,080 results on '"Kastelein, John J.P."'

102. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia

Author

Universidad de Sevilla. Departamento de Medicina, Brandts, Julia, Dharmayat, Kanika I., Vallejo Vaz, Antonio Javier, Azar Sharabiani, Mansour Taghavi, Jones, Rebecca, Kastelein, John J.P., Raal, Frederick J., Ray, Kausik K., Universidad de Sevilla. Departamento de Medicina, Brandts, Julia, Dharmayat, Kanika I., Vallejo Vaz, Antonio Javier, Azar Sharabiani, Mansour Taghavi, Jones, Rebecca, Kastelein, John J.P., Raal, Frederick J., and Ray, Kausik K.

Abstract

Background and aims Several medications targeting PCSK9 reduce LDL-cholesterol (LDL-C) in heterozygous familial hypercholesterolemia (HeFH). We aimed to assess in patients diagnosed clinically as HeFH, whether LDL-C reduction varied by different therapeutic approaches to PCSK9-targeting or by the underlying genetic variant. Methods We conducted a random-effects meta-analysis of randomised clinical trials assessing PCSK9-targeting therapies, namely alirocumab, evolocumab and inclisiran, in patients with clinically diagnosed HeFH and restricted analyses to those patients in whom genotypic data were available. A search of MEDLINE and Embase identified eligible trials published between inception and June 29, 2020. We included trials of sufficient duration to allow for a stable treatment effect: ~12 weeks for monoclonal antibodies (mAbs) (alirocumab, evolocumab) and ~1 year for small interfering RNA (siRNA) (inclisiran). Single-moderator meta-regression comparing mean percentage LDL-C reduction between mAbs and siRNA as well as PCSK9-targeting therapies between different genotypes was used to assess heterogeneity. Results Eight trials of HeFH met our inclusion criteria, including 1887 genotyped patients. Among monogenic HeFH cases (N = 1347) the LDL-C reduction from baseline was 46.12% (95%CI 48.4-43.9) for siRNA and 50.4% (59.3-41.4) for mAbs compared to control, without evidence of significant heterogeneity between treatment (QM = 0.32, df = 1, p = 0.57). Irrespective of therapeutic approach to PCSK9-targeting, reductions in LDL-C were generally consistent across genetic variants (LDL-Receptor variants, LDL-Receptor variants of unknown significance, Apolipoprotein B variants, two variants and no variant) (QM = 8.3, df = 4, p = 0.08). Conclusions Among patients with HeFH, the LDL-C-lowering effect of PCSK9-targeting medications did not show statistical heterogeneity across different drug-classes and across genetic variants.

Published
2021

111. Statin therapy with ezetimibe or niacin in high-risk patients

Author

Kastelein, John J.P. and Bots, Michiel L.

Subjects
Atherosclerosis -- Drug therapy, Atherosclerosis -- Risk factors, Cholesterol, LDL -- Health aspects, Niacin -- Usage, Niacin -- Health aspects, Drug therapy, Combination
Abstract

The authors comment on the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies (ARBITER 6-HALTS) study on the use of ez etimibe or extended-release niacin together with statin in patients at high risk of atherosclerosis. They assert the study's findings support the concept that using statins to reduce LDL cholesterol together with niacin to raise HDL cholesterol levels is more effective in patients with high cardiovascular risk.

Published
2009

112. A randomized trial of rosuvastatin in the prevention of venous thromboembolism

Author

Glynn, Robert J., Danielson, Eleanor, Francisco, M.I.A, Fonseca, A.H., Genest, Jacques, Gotto, Antonio M., Jr., Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFadyen, Jean G., Nordestgaard, Borge C., Shepherd, James, Willerson, James T., and Ridker, Paul M.

Subjects
Thromboembolism -- Drug therapy, Thromboembolism -- Prevention, Rosuvastatin -- Usage, Rosuvastatin -- Health aspects
Abstract

The effects of the stain therapy and use of rosuvastatin on the prevention of venous thromboembolism are analyzed. The results indicate that venous thromboembolism can be easily prevented in healthy persons by an effective use of rosuvastatin.

Published
2009

113. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia

Author

Meuwese, Marijn C., de Groot, Eric, Duivenvoorden, Raphael, Trip, Mieke D., Ose, Leiv, Maritz, Frans J., Basart, Dick C. G., Kastelein, John J.P., Habib, Rafik, Davidson, Michael H., Schwocho, Lee R., and Stein, Evan A

Subjects
Atherosclerosis -- Prevention, Atherosclerosis -- Care and treatment, Atherosclerosis -- Drug therapy, Cardiovascular agents -- Evaluation, Hypercholesterolemia -- Care and treatment
Abstract

The study evaluates the efficacy of the inhibition of the intracellular enzyme acyle coenzyme, A:cholesterol acyltransferase (ACAT), with pactimibe in the prevention of atherosclerosis in patients with familial hypercholesterolemia. Results show pactimibe had no effect on atherosclerosis as measured by maximum changes in carotid intima-media thickness (CIMT), but was associated with an increase in mean CIMT and higher incidence of major cardiovascular events.

Published
2009

115. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Author

Ridker, Paul M., Danielson, Eleanor, Fonseca, Francisco A.H., Genest, Jacques, Gotto, Antonio M. Jr, Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFayden, Jean G., Nordestgaard, Borge G., Shepherd, James, Willerson, James T., and Glynn, Robert J.

Subjects
C-reactive protein -- Health aspects, Cardiovascular diseases -- Prevention, Cardiovascular diseases -- Drug therapy, Rosuvastatin -- Usage
Abstract

A study was conducted to evaluate the efficacy of Rosuvastatin as a means of preventing cardiovascular events in men and women with elevated C-reactive protein. Results indicated that rosuvastatin significantly reduced the incidence of cardiovascular events in men and women.

Published
2008

116. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease

Author

Shepherd, James, Kastelein, John J.P., Bittmer, Vera A., Carmena, Rafael, Deedwania, Prakash C., Breazna, Andrei, Dobson, Stephen, Wilson, Daniel J., Zuckerman, Andrea L., and Wenger, Nanette K.

Subjects
Lipids -- Control, Coronary heart disease -- Drug therapy, Coronary heart disease -- Patient outcomes, Type 2 diabetes -- Drug therapy, Type 2 diabetes -- Patient outcomes, Chronic kidney failure -- Drug therapy, Chronic kidney failure -- Patient outcomes
Abstract

OBJECTIVE: To investigate the effect of intensive lipid lowering with high-dose atorvastatin on the incidence of major cardiovascular events compared with low-dose atorvastatin in patients with coronary artery disease and [...]

Published
2008

117. Simvastatin with or without Ezetimibe in familial Hypercholesterolemia

Author

Kastelein, John J.P., Stroes, Erik S.G., Akdim, Fatima, Zwinderman, Aeilko H., Bots, Michiel L., Stalenhoef, Anton F.H., Visseren, Frank L.J., Sijbrands, Eric J.G., Trip, Mieke D, Stein, Evan A., Gaudet, Daniel, Duivenvoorden, Raphael, Veltri, Enrico P., Marais, A. David, and de Groot, Eric

Subjects
Atherosclerosis -- Care and treatment, Hypercholesterolemia -- Health aspects, Hypercholesterolemia -- Research, Blood lipoproteins -- Health aspects, Lipoproteins -- Health aspects, Proteolipids -- Health aspects
Abstract

A study to explain the efficacy of ezetimibe, which reduces LDL cholesterol on the progression of atherosclerosis, is conducted. Results indicate that a combination of simvastatin and ezetimibe does not show any significant changes in hypercholesterolemia but simvastatin alone did work better.

Published
2008

118. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized control trial

Author

Nissen, Steven E., Nicholls, Stephen J., Wolski, Kathy, Rodes-Cabau, Josep, Cannon, Christopher P., Deanfield, John E., Despres, Jean-Pierre, Kastelein, John J.P., Steinhubl, Steven R., Kapadia, Samir, Yasin, Muhammad, Ruzyllo, Witold, Gaudin, Christophe, Job, Bernard, Bo, Hu, Bhatt, Deepak L., Lincoff, A. Michael, and Tuzeu, E. Murat

Subjects
Atherosclerosis -- Health aspects, Coronary heart disease -- Care and treatment, Obesity -- Risk factors, Obesity -- Care and treatment
Abstract

A study is conducted to evaluate whether weight loss and metabolic effects of rimonobant are successful in reducing the onset of coronary artery disease in patients with abdominal obesity and metabolic syndrome. Results conclude that rimonobant is not very effective but does help in weight loss and reduction in waist size, improves lipid profiles and so is good in prevention of coronary heart disease.

Published
2008

119. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

Author

Santos, Raul D., Ruzza, Andrea, Hovingh, G. Kees, Wiegman, Albert, Mach, François, Kurtz, Christopher E., Hamer, Andrew, Bridges, Ian, Bartuli, Andrea, Bergeron, Jean, Szamosi, Tamás, Santra, Saikat, Stefanutti, Claudia, Descamps, Olivier S., Greber-Platzer, Susanne, Luirink, Ilse, Kastelein, John J.P., Gaudet, Daniel, HAUSER-RCT INVESTIGATORS, Stéphenne, Xavier, Sokal, Etienne, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Experimental Vascular Medicine, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Paediatric Metabolic Diseases, General Paediatrics, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, APH - Methodology, APH - Quality of Care, ACS - Heart failure & arrhythmias, ACS - Diabetes & metabolism, and ACS - Pulmonary hypertension & thrombosis

Subjects
Male, medicine.medical_specialty, Heterozygote, animal structures, Adolescent, medicine.drug_class, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Monoclonal antibody, Antibodies, LDL, Hyperlipoproteinemia Type II, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Double-Blind Method, Drug Therapy, Internal medicine, Monoclonal, medicine, Humans, 030212 general & internal medicine, Child, Humanized, biology, Cholesterol, business.industry, Anticholesteremic Agents, fungi, Antibodies, Monoclonal, Humanized, Cholesterol, LDL, Drug Therapy, Combination, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Proprotein Convertase 9, Treatment Outcome, General Medicine, Proprotein convertase, medicine.disease, Evolocumab, Endocrinology, chemistry, Combination, biology.protein, lipids (amino acids, peptides, and proteins), Antibody, business, Lipoprotein
Abstract

Background: Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known. Methods: We conducted a 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia. Patients 10 to 17 years of age who had received stable lipid-lowering treatment for at least 4 weeks before screening and who had an LDL cholesterol level of 130 mg per deciliter (3.4 mmol per liter) or more and a triglyceride level of 400 mg per deciliter (4.5 mmol per liter) or less were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab (420 mg) or placebo. The primary end point was the percent change in LDL cholesterol level from baseline to week 24; key secondary end points were the mean percent change in LDL cholesterol level from baseline to weeks 22 and 24 and the absolute change in LDL cholesterol level from baseline to week 24. Results: A total of 157 patients underwent randomization and received evolocumab (104 patients) or placebo (53 patients). At week 24, the mean percent change from baseline in LDL cholesterol level was -44.5% in the evolocumab group and -6.2% in the placebo group, for a difference of -38.3 percentage points (P

Published
2020

121. Effects of torcetrapid in patients at high risk for coronary events

Author

Barter, Philip J., Caulfield, Mark, Eriksson, Mats, Grundy, Scott M., Kastelein, John J.P., Komajda, Michel, Lopez-Sendon, Jose, Mosca, Lori, Tardif, Jean-Claude, Waters, David D., Shear, Charles L., Revkin, James H., Buhr, Kevin A., Risher, Marian R., Tall, Alan R., and Brewer, Bryan

Subjects
Torcetrapib (Medication) -- Research, Torcetrapib (Medication) -- Complications and side effects, Anticholesteremic agents -- Research, Anticholesteremic agents -- Complications and side effects, Heart -- Abnormalities, Heart -- Risk factors
Abstract

A randomized, double-blind trial was conducted to determine efficacy of torcetrapib, a potent cholesteryl ester transfer protein inhibitor to reduce major cardiovascular events. The trial was terminated prematurely as it increased risk of death and cardiac events in patients receiving torcetrapib.

Published
2007

122. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

Author

Kastelein, John J.P., van Leuven, Sander I, Burgess, Leslie, Evans, Greg W., Kuivenhoven, Jan A., Barter, Philip J., Revkin, James H., Grobbee, Diederick E., Riley, Ward A., Shear, Charles L., Duggan, William T., and Bots, Michiel L.

Subjects
Hypercholesterolemia -- Drug therapy, Atherosclerosis -- Drug therapy, High density lipoproteins -- Research, Anticholesteremic agents -- Dosage and administration
Abstract

A trial is conducted to test if torcetrapib, an inhibitor of cholesteryl ester transfer protein can minimize atherosclerotic vascular disease by raising the levels of high-density lipoprotein (HDL) cholesterol in 850 patients with heterozygous familial hypercholesterolemia. It is concluded that use of torcetrapib with atorvastatin, did not reduce the progress of atherosclerosis, inspite of substantial, rise in the level of HDL cholesterol and reduction the LDL cholesterol and triglycerides level.

Published
2007

123. Low plasma adiponectin exacerbates the risk of premature coronary heart disease in familial hypercholesterolemia

Author

Perron, Patrice, Brisson, Diane, Laprise, Catherine, St-Pierre, Julie, Gaudet, Daniel, Tremblay, Gérald, Bouhali, Tarek, Vohl, Marie-Claude, Després, Jean-Pierre, Vissers, Maud N., Hutten, Barbara A., Kastelein, John J.P., Perron, Patrice, Brisson, Diane, Laprise, Catherine, St-Pierre, Julie, Gaudet, Daniel, Tremblay, Gérald, Bouhali, Tarek, Vohl, Marie-Claude, Després, Jean-Pierre, Vissers, Maud N., Hutten, Barbara A., and Kastelein, John J.P.

Abstract

Familial hypercholesterolemia (FH) is characterized by increased risk for premature coronary artery disease (CAD). This risk is exacerbated in the presence of abdominal obesity and insulin resistance. Low adiponectin is part of the clustering of metabolic abnormalities associated with abdominal obesity and insulin resistance. The present study, therefore, aims to examine the relationship between plasma adiponectin and age at CAD diagnosis in FH patients. Plasma adiponectin was measured by ELISA in 568 non-diabetic FH individuals of French-Canadian origin. CAD was defined according to strict clinical criteria. Prior to analyses, patients were grouped according to age and gender-specific tertiles of plasma adiponectin levels. Multivariate Cox proportional hazards regression was used to estimate the association between plasma adiponectin levels and age at diagnosis of CAD. Overall, FH patients in the lowest tertile of plasma adiponectin exhibited CAD at a significantly younger age (hazard ratio = 1.73, confidence interval 95%: [1.19–2.53]; p = 0.004). These results suggest that low plasma adiponectin is associated with an increased risk of premature CAD over and above the already exaggerated risk seen in FH patients.

Published
2020

130. Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

Author

Ridker, Paul M., Fonseca, Francisco A.H., Genest, Jacques, Gotto, Antonio M., Kastelein, John J.P., Khurmi, Nardev S., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., Nordestgaard, Borge G., Shepherd, James, Willerson, James T., and Glynn, Robert J.

Published
2007
Full Text
View/download PDF

133. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

Author

Deedwania, Prakash, Barter, Philip, Carmena, Rafael, Fruchart, Jean-Charles, Grundy, Scott M., Haffner, Steven, Kastelein, John J.P., LaRosa, John C., Schachner, Holly, Shepherd, James, and Waters, David D.

Subjects
American Heart Association -- Research, Coronary heart disease -- Research, Coronary heart disease -- Care and treatment, Coronary heart disease -- Analysis, Low density lipoprotein receptors -- Research, Low density lipoprotein receptors -- Analysis, Low density lipoprotein receptors -- Care and treatment, Metabolic syndrome X -- Research, Metabolic syndrome X -- Analysis
Published
2006

134. The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study

Author

Hovingh, Kees G., Smits, Loek P., Stefanutti, Claudia, Soran, Handrean, Kwok, See, de Graaf, Jacqueline, Gaudet, Daniel, Keyserling, Constance H., Klepp, Heather, Frick, Jennifer, Paolini, John F., Dasseux, Jean-Louis, Kastelein, John J.P., and Stroes, Erik S.

Published
2015
Full Text
View/download PDF

135. Increased carotid and femoral intima-media thickness in patients after repair of aortic coarctation: Influence of early repair

Author

Vriend, Joris W.J., De Groot, Eric, De Waal, Tim T., Zijta, Frank M., Kastelein, John J.P., and Mulder, Barbara J.M.

Subjects
Aortic coarctation, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2005.02.013 Byline: Joris W.J. Vriend (a), Eric de Groot (b), Tim T. de Waal (b), Frank M. Zijta (b), John J.P. Kastelein (b), Barbara J.M. Mulder (a) Abstract: In patients, after repair of aortic coarctation, abnormal function of the proximal precoarctation arterial conduits has been demonstrated, but data on arterial wall structure of proximal and distal arteries in patients are scarce. The aim of our study is to compare intima-media thickness (IMT) of the carotid and femoral arteries in controls and patients after coarctation repair and to identify independent predictors of carotid and femoral IMT. Author Affiliation: (a) Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (b) Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Article History: Received 10 September 2004; Accepted 14 February 2005

Published
2006

136. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

Author

Gibson, C. Michael, primary, Kastelein, John J.P., additional, Phillips, Adam T., additional, Aylward, Philip E., additional, Yee, Megan K., additional, Tendera, Michal, additional, Nicholls, Stephen J., additional, Pocock, Stuart, additional, Goodman, Shaun G., additional, Alexander, John H., additional, Lincoff, A. Michael, additional, Bode, Christoph, additional, Duffy, Danielle, additional, Heise, Mark, additional, Berman, Gail, additional, Mears, Sojaita Jenny, additional, Tricoci, Pierluigi, additional, Deckelbaum, Lawrence I., additional, Steg, P. Gabriel, additional, Ridker, Paul, additional, and Mehran, Roxana, additional

Published
2021
Full Text
View/download PDF

138. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction

Author

Pedersen, Terje R., Szarek, Michael, Tsai, John, Faergemann, Ole, Lindahl, Christina, Kastelein, John J.P., Bendiksen, Fredrik S., Olsson, Anders G., Larsen, Mogens Lytken, Tikkanen, Matti J., and Holme, Ingar

Subjects
Heart attack -- Drug therapy, Simvastatin -- Dosage and administration, Simvastatin -- Comparative analysis
Abstract

The effects of two strategies of lipid lowering on the risk of cardiovascular disease among patients with a previous myocardial infarction (MI) are compared. Results reveal that patients with MI might benefit from intensive lowering of low-density lipoprotein cholesterol (LDL-C) without an increase in noncardiovascular mortality or other serious adverse reactions.

Published
2005

139. Intensive lipid lowering with atorvastatin in patients with stable coronary disease

Author

LaRosa, John C., Fruchart, Jean-Charles, Wenger, Nanette K., Gotto, Antonio M., Grundy, Scott M., Waters, David D., Greten, Heiner, Shear, Charles, Kastelein, John J.P., Barter, Philip, and Shepherd, James

Subjects
Coronary heart disease -- Care and treatment, Cholesterol, LDL -- Measurement
Abstract

Lowering low-density lipoprotein (LDL) cholesterol levels below recommended levels is beneficial in patients with acute coronary syndromes. Intensive lipid-lowering therapy with 80mg of atorvastatin per day in patients with stable coronary heart disease (CHD) provides significant clinical benefit beyond that afforded by treatment with 10mg of atorvastatin per day.

Published
2005

140. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: design and rationale of the Ezetimibi and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial

Author

Kastelein, John J.P., Sager, Philip T., Groot, Eric de, and Veltri, Enrico

Subjects
Hypercholesterolemia -- Drug therapy, Atherosclerosis -- Drug therapy, Simvastatin -- Evaluation, Simvastatin -- Comparative analysis, Health, Ezetimibi (Medication) -- Evaluation, Ezetimibi (Medication) -- Comparative analysis
Published
2005

146. Loci influencing blood pressure identified using a cardiovascular gene-centric array

Author

Ganesh, Santhi K., Tragante, Vinicius, Guo, Wei, Guo, Yiran, Lanktree, Matthew B., Smith, Erin N., Johnson, Toby, Castillo, Berta Almoguera, Barnard, John, Baumert, Jens, Chang, Yen-Pei Christy, Elbers, Clara C., Farrall, Martin, Fischer, Mary E., Franceschini, Nora, Gaunt, Tom R., Gho, Johannes M.I.H., Gieger, Christian, Gong, Yan, Isaacs, Aaron, Kleber, Marcus E., Leach, Irene Mateo, McDonough, Caitrin W., Meijs, Matthijs F.L., Mellander, Olle, Molony, Cliona M., Nolte, Ilja M., Padmanabhan, Sandosh, Price, Tom S., Rajagopalan, Ramakrishnan, Shaffer, Jonathan, Shah, Sonia, Shen, Haiqing, Soranzo, Nicole, van der Most, Peter J., Van Iperen, Erik P.A., Van Setten, Jessic A., Vonk, Judith M., Zhang, Li, Beitelshees, Amber L., Berenson, Gerald S., Bhatt, Deepak L., Boer, Jolanda M.A., Boerwinkle, Eric, Burkley, Ben, Burt, Amber, Chakravarti, Aravinda, Chen, Wei, Cooper-DeHoff, Rhonda M., Curtis, Sean P., Dreisbach, Albert, Duggan, David, Ehret, Georg B., Fabsitz, Richard R., Fornage, Myriam, Fox, Ervin, Furlong, Clement E., Gansevoort, Ron T., Hofker, Marten H., Hovingh, G. Kees, Kirkland, Susan A., Kottke-Marchant, Kandice, Kutlar, Abdullah, LaCroix, Andrea Z., Langaee, Taimour Y., Li, Yun R., Lin, Honghuang, Liu, Kiang, Maiwald, Steffi, Malik, Rainer, Murugesan, Gurunathan, Newton-Cheh, Christopher, OʼConnell, Jeffery R., Onland-Moret, N. Charlotte, Ouwehand, Willem H., Palmas, Walter, Penninx, Brenda W., Pepine, Carl J., Pettinger, Mary, Polak, Joseph F., Ramachandran, Vasan S., Ranchalis, Jane, Redline, Susan, Ridker, Paul M., Rose, Lynda M., Scharnag, Hubert, Schork, Nicholas J., Shimbo, Daichi, Shuldiner, Alan R., Srinivasan, Sathanur R., Stolk, Ronald P., Taylor, Herman A., Thorand, Barbara, Trip, Mieke D., van Duijn, Cornelia M., Verschuren, W. Monique, Wijmenga, Cisca, Winkelmann, Bernhard R., Wyatt, Sharon, Young, J. Hunter, Boehm, Bernhard O., Caulfield, Mark J., Chasman, Daniel I., Davidson, Karina W., Doevendans, Pieter A., FitzGerald, Garret A., Gums, John G., Hakonarson, Hakon, Hillege, Hans L., Illig, Thomas, Jarvik, Gail P., Johnson, Julie A., Kastelein, John J.P., Koenig, Wolfgang, März, Winfried, Mitchell, Braxton D., Murray, Sarah S., Oldehinkel, Albertine J., Rader, Daniel J., Reilly, Muredach P., Reiner, Alex P., Schadt, Eric E., Silverstein, Roy L., Snieder, Harold, Stanton, Alice V., Uitterlinden, André G., van der Harst, Pim, van der Schouw, Yvonne T., Samani, Nilesh J., Johnson, Andrew D., Munroe, Patricia B., de Bakker, Paul I.W., Zhu, Xiaofeng, Levy, Daniel, Keating, Brendan J., and Asselbergs, Folkert W.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results